Clinical Trials
59 trialsBRIDGE
Sun Yat-sen University
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
PDT For Induction Therapy For Head And Neck Cancer
Massachusetts General Hospital
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Dana-Farber Cancer Institute
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
Hokkaido University Hospital
TPFmORL
Groupe Oncologie Radiotherapie Tete et Cou
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
Toripalimab With Chemotherapy for Sinus Cancer
Dana-Farber Cancer Institute
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Dana-Farber Cancer Institute
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
City of Hope Medical Center
Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer
Institute of Oncology Ljubljana
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer
Assiut University
Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC
Shanghai Jiao Tong University School of Medicine
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Dana-Farber Cancer Institute
Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer
George Washington University
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
Eastern Cooperative Oncology Group
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN
University of Pittsburgh
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
University of Kentucky
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer
Shin Kong Wu Ho-Su Memorial Hospital
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Wake Forest University Health Sciences
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Samsung Medical Center
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
Barbara Ann Karmanos Cancer Institute
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
Radiation Therapy Oncology Group
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Masonic Cancer Center, University of Minnesota
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
University of Miami
DREXNECK
Drexel University
Docetaxel in Treating Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC
Lithuanian University of Health Sciences
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Case Comprehensive Cancer Center
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Efficacy and Safety of Ultrasound Hyperthermia Combined With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
University of Michigan Rogel Cancer Center
Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
Seoul National University Hospital
Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer
Minneapolis Veterans Affairs Medical Center
S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
SWOG Cancer Research Network
Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx
National Cancer Institute (NCI)
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
TPSHNSCC
Chonnam National University Hospital
S0217
SWOG Cancer Research Network